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Objectives: Bronchiolitis obliterans is the greatest limitation to the long-term
applicability of lung transplantation. Although alloimmune events are important,
nonimmune events, such as gastroesophageal reflux, might contribute to lung injury
and the development of bronchiolitis obliterans syndrome.
Methods: We retrospectively studied the 396 patients who underwent lung trans-
plantation at the Duke Lung Transplant Program from April 1992 to April 2002.
Reflux was assessed for using an ambulatory 24-hour esophageal pH probe.
Results: Reflux assessment with an esophageal pH probe was obtained in 128
patients after lung transplantation. Abnormal pH study results were present in 93
(73%) patients. Forty-three patients underwent a surgical fundoplication. There was
no in-hospital or 30-day mortality in the patients undergoing fundoplication. At the
time of fundoplication, 26 patients met the criteria for bronchiolitis obliterans
syndrome. After fundoplication, 16 patients had improved bronchiolitis obliterans
syndrome scores, with 13 of these patients no longer meeting the criteria for
bronchiolitis obliterans syndrome. In patients at least 6 months after lung transplan-
tation and 6 months after fundoplication, the forced expiratory volume in 1 second
improved by an average of 24% (mean forced expiratory volume in 1 second before
fundoplication, 1.87 L; mean forced expiratory volume in 1 second after fundopli-
cation, 2.19 L/sec; P  .0002). Overall actuarial survival was significantly better in
patients who had either normal pH studies or who had fundoplication.
Conclusions: Gastroesophageal reflux disease is very common after lung transplan-
tation and appears to contribute to mortality and development of bronchiolitis
obliterans syndrome. Fundoplication in lung transplant recipients with gastroesoph-
ageal reflux disease is associated with significant improvements in lung function,
particularly if performed before the late stages of bronchiolitis obliterans syndrome.
Lung transplantation has evolved into an effective treatment for pa-tients with end-stage lung disease, with many centers reportinggreater than 80% 1-year survival. As immediate posttransplant sur-gical outcomes have improved, the greatest limitation of lung trans-plantation remains chronic allograft dysfunction or bronchiolitisobliterans syndrome (BOS). Five-year patient survival remains a
disappointing 40%.1,2
BOS is a clinical syndrome manifested by decreases in the forced expiratory
volume in 1 second (FEV1).3,4 BOS is a surrogate marker for chronic rejection,
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which is manifested pathologically by scar formation and
fibrosis of the small airways that defines the pathologic
entity termed obliterative bronchiolitis. The incidence of
BOS increases with time and is greater than 60% by 5 years
after transplantation.5-8 The lung, as compared with other
organs, appears to be significantly more susceptible to
chronic injury. Although 5-year allograft survival from the
United Network for Organ Sharing (UNOS) registry is 68%
and 63% for the heart and cadaveric kidney, respectively,
lung allograft survival was only 42%.1
The pathogenesis of chronic lung dysfunction is poorly
understood. Although chronic immunologic injury is impli-
cated, treatment of patients with bronchiolitis obliterans-
BOS by augmenting or altering immunosuppression rarely
reverses the lung dysfunction. Several therapies have been
attempted, and although a few have resulted in stabilization
of the patients’ pulmonary status, results from treatment
have been generally disappointing. Despite attempts to re-
verse or stabilize the patient’s pulmonary status, progres-
sion of the chronic rejection process occurs frequently.9-18
Previous studies have identified several risk factors for
the development of BOS, including frequent, severe, or both
early acute rejection episodes; cytomegalovirus (CMV) in-
fection and pneumonia; mismatches at human HLA loci;
and development of antibodies to class I HLA.7,19-22 Recent
reports have suggested that gastroesophageal reflux with
resultant aspiration could contribute to the allograft dys-
function, representing a potential cause of BOS.23,24
Gastroesophageal reflux disease (GERD) has a high
prevalence in patients with a variety of lung diseases, par-
ticularly patients with asthma, cystic fibrosis, and pulmo-
nary fibrosis.25-30 In patients after pneumonectomy, there
are marked abnormalities in esophageal function and re-
flux.31 GERD has been associated with the development of
bronchiolitis obliterans with organizing pneumonia.32 For
multiple reasons (the use of immunosuppressive drugs and
vagal nerve injury during the operation), GERD might be
increased after lung transplantation. Additionally, host de-
fense mechanisms of the lung, including the cough reflux
and mucociliary clearance of foreign bodies, is markedly
impaired.33-37
In this study we hypothesize that GERD causing repet-
itive gastric aspiration produces chronic lung injury and that
prevention of gastric reflux with fundoplication would im-
prove lung function.
Patients and Methods
We retrospectively analyzed 396 consecutive lung transplantations
performed at Duke University Medical Center from April 1992 to
April 2002. Standard operative techniques were used. Demo-
graphic data, including time of transplant, sex, age, type, and
survival, was collected on all patients. For comparison, allograft
survival data for kidney and heart transplants performed at Duke
from 1990 to 2002 were obtained. Lung transplant recipients
underwent routine FEV1 measurements at each clinic visit or at
any time if they showed clinical evidence of deterioration. The
most recent FEV1 values were then compared with the best FEV1
value obtained by the patients after transplantation.
The diagnosis of chronic rejection, BOS, was made on the basis
of pulmonary function data according to International Society for
Heart and Lung Transplantation (ISHLT) criteria.3 The diagnosis
of BOS requires a 20% or greater decrease in pulmonary function
from a patient’s baseline value and the exclusion of other causes of
decreasing lung function, including narrowing of the anastomosis,
acute rejection, or infection. Recipients were considered at risk for
BOS only if they survived 6 or more months after transplantation.
For the analysis, a BOS score of 1 or greater was considered
positive, whereas a BOS score of 0 was considered negative.
A subset of this series of lung transplantation had been evalu-
ated for GERD, and data on this group, including date of pH study
and result, were included. A subset of this smaller group under-
went treatment for GERD by means of surgical fundoplication, and
data, including results, prefundoplication and postfundoplication
FEV1 values, and survival, were tabulated on this series. Standard
laparoscopic techniques were used for the majority of fundoplica-
tions, and when converted to open procedures, standard operative
techniques were used.
pH Probe Studies
GERD was assessed in 128 patients after lung transplantation by
using 24-hour ambulatory pH probe studies. Proton pump inhibi-
tors were discontinued for at least 5 days before the pH studies.
Histamine (H-2) blockers and promotility agents were stopped at
least 24 hours before the studies. The esophageal pH laboratory at
Duke University Medical Center uses standard techniques.38 A
distal esophageal probe was inserted in a standardized manner by
one technician in all patients. The probe was removed after ap-
proximately 24 hours. Patients were instructed to go on with their
daily activities as usual. A small number of nonselected patients
also had a proximal pH probe placed in the esophagus. The
correlation between the distal and the proximal probe measure-
ments was good, and therefore there was no need for a proximal
probe in all patients. Abnormal acidity in the esophagus was
recorded every time the pH decreased to less than 4. The results
were reported as the percentage of abnormal acid contact time at
the distal esophagus. Normal values for acid contact times were as
follows: total less than 5%, upright less than 8%, and supine less
than 3%.
Early in the series, patients selected for pH studies were sus-
pected of having GERD on the basis of symptoms, clinical con-
cerns (eg, vocal cord erythema and inflammation on bronchoscopy
or foreign material consistent with aspiration on biopsy), or an
unexplained decrease in FEV1 value. From March 1998 until July
2000, patients were studied prospectively under an institutional
review board protocol. Because of the high prevalence of GERD
and demonstrable improvements in FEV1 values in patients with
GERD after fundoplication, from July 2000, pH studies were
performed liberally as part of routine clinical practice.
Immunosuppression
After lung transplantation, all patients received similar immuno-
suppression. From 1992 until May 2000, patients received cyclo-
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sporine (INN: ciclosporin; 5-10 mg  kg1  d1), aiming for a
target trough level of 250 to 300 ng/mL (high-performance liquid
chromatography). After May 2000, tacrolimus was used initially
sublingually followed by oral administration, aiming for a target
trough level between 10 and 15 ng/mL. Azathioprine (1-2 mg 
kg1  d1) was used throughout. From 1997 to 1998, patients
received either azathioprine or mycophenolate (1 g twice daily) as
part of an ongoing randomized study in addition to cyclosporine or
prednisone. Patients received intravenous methylprednisolone
(500 mg per lung intraoperatively, followed by 125 mg every 12
hours for 4 doses), followed by prednisone (initially at 20 mg/d).
Induction therapy with rabbit antithymocyte globulin was used in
22 patients from 1994 to 1996 as part of a previous randomized
study. From January 1999, induction therapy with an anti-CD25
monoclonal antibody (1 mg/kg daclizumab or 20 mg of basilix-
imab on days 0 and 4) was used.
Episodes of acute allograft rejection were treated with 500
mg/d methylprednisolone for 3 days, followed by a 2-week oral
prednisone taper. Refractory or persistent rejection was treated
with rabbit antithymocyte globulin, antithymocyte gamma-globu-
lin, or, most recently, alemtuzumab. Additionally, cyclosporine
was changed to tacrolimus and azathioprine to mycophenolate
mofetil in many patients.
Infection Prophylaxis
All patients at risk for CMV infection (positive donor or recipient
serology) received prophylaxis with ganciclovir. All patients re-
ceived Pneumocystis carinii prophylaxis indefinitely. Fungal in-
fection prophylaxis consisted of nystatin swish and swallow for the
first 6 months after transplantation. In addition, since January
1997, aerosolized amphotericin B (either liposomal or conven-
tional) was given for at least 2 weeks after transplantation. Van-
comycin and ceftazidime were used for bacterial infection prophy-
laxis the first 2 weeks after transplantation. In patients with septic
lung disease, antibiotic choice was individualized and guided by
pretransplant cultures.
Statistical Analysis
Differences between FEV1 values before and after fundoplication
were compared by using a paired 2-tailed t test. Demographic data
between groups was assessed by using 2 analysis. Overall sur-
vival was determined by using Kaplan-Meier actuarial analysis.
Differences in actuarial freedom between groups were determined
with the log-rank test. Data analysis was performed with NCSS
2000 software (NCSS, Kaysville, Utah). Values were reported as
means SEM except for age, which was reported as means SD.
Results
In the decade from its inception in April 1992, The Duke
Lung Transplant Program has performed 396 lung trans-
plantations. Since 1997, we have performed pH studies on
128 patients after lung transplantation. Forty-three patients
have subsequently undergone fundoplication surgery.
pH Studies
Of the 128 patients evaluated with a 24-hour ambulatory pH
probe, 93 (73%) had abnormal pH study results. In patients
with abnormal pH study results, the average total, supine,
and upright values were 13.1% 0.9%, 14.3% 1.1%, and
11.9% 1.2%, respectively. For the 35 (27%) patients with
normal pH studies, the average total, supine, and upright
values were 2.0%  0.3%, 2.8%  0.4%, and 0.5% 
0.2%, respectively. There was no statistical difference in
respect to age, sex, transplant type, or pretransplant diag-
nosis between the patients with normal and those with
abnormal pH study results (Table 1).
The pH study results were obtained an average of 507
days (range, 29-2502 days) after transplantation. At the time
of the studies, 33 (26%) of the patients met the criteria for
BOS.




without reflux P value
No. of patients 93 (73%) 35 (27%)
Average age (y) 47 14 51 12 NS
Sex (%)
Female 41 (44) 21 (60) NS
Male 52 (5) 14 (40) NS
Underlying disease (%)
CF/bronchiectasis 22 (24) 7 (20) NS
COPD/A1A def 51 (55) 21 (60) NS
OB/Rtx 2 (2) 1 (3) NS
IPF 9 (10) 2 (6) NS
PPH 2 (2) 1 (3) NS
Other 7 (8) 3 (9) NS
Type of transplant (%)
Bilateral 57 (61) 26 (74) NS
Single 36 (39) 9 (26) NS
CF, Cystic fibrosis; COPD, chronic obstructive pulmonary disease; AIA def, i-antitrypsin deficiency; OB, obliterative bronchiolitis; Rtx, retransplantation; IPF,
idiopathic pulmonary fibrosis; PPH, primary pulmonary hypertension; NS, not significant.
Davis et al General Thoracic Surgery
The Journal of Thoracic and Cardiovascular Surgery ● Volume 125, Number 3 535
G
TS
Of the patients studied who met the criteria for BOS at
the time of their pH study, 25 (76%) had abnormal pH
values, and 8 (24%) had normal pH values.
Fundoplication Group
We have performed antireflux operations in 43 patients
undergoing lung transplantation, with the majority of oper-
ations being laparoscopic Nissens. Three cases were per-
formed as open procedures because of extensive adhesions,
and 4 laparoscopic toupee wraps were performed. In 10
patients abnormal gastric emptying was demonstrated in an
abnormal nuclear medicine solid gastric emptying study. In
these patients the following additional gastric drainage pro-
cedures were performed: there were 6 pyloroplasties and 1
gastrojejunostomy, and 2 patients received both a gastros-
tomy tube for drainage and a jejunostomy tube for alimen-
tary access. One patient did not receive any additional
drainage procedure. There was no in-hospital or 30-day
mortality after the fundoplication operations.
Indications for fundoplication were an abnormal pH
study in 39 patients, severe reflux documented by barium
swallow but with normal esophageal manometry in 2 pa-
tients, retransplant for a patient with presumed repetitive
aspiration based on pathology of the explanted lung dem-
onstrating predominantly lipid pneumonia, and in 1 patient
on the basis of repetitive episodes of aspiration pneumonia.
In the patients with pH studies, the percentages of average
acid contact times were as follows: 17.5%  1.2%, 18.7%
 1.6%, and 15.5%  2.0% for the total, upright, and
supine values, respectively.
In terms of demographics between the lung transplant
recipients undergoing a fundoplication operation and the
overall series, there were no significant differences between
the 2 groups in terms of age, sex, type of transplant, or
pretransplant diagnosis (Table 2).
In terms of risk factors for chronic allograft rejection,
there was no difference between the 2 groups in terms of
increased pretransplant panel-reactive antibody screening,
CMV infections, or mismatches at HLA loci. There were
more episodes of early and severe acute rejection episodes
seen in the fundoplication group (P  .04).
FEV1/BOS
In the lung transplant recipients who underwent fundopli-
cation, the FEV1 value significantly improved after the
surgical treatment for documented GERD. The average
FEV1 value before antireflux surgery was 1.87 L, and when
re-evaluated at least 6 months after antireflux surgery, the
FEV1 value had increased to 2.19 L, representing an in-
crease of 24.1% (Figure 1). Greater than 80% of lung
transplant recipients who also underwent antireflux surgery
for documented GERD had improvements in their FEV1
values after fundoplication.
Of the 43 patients undergoing fundoplication, 26 (60%)
met he criteria for the development of BOS at the time of
their antireflux operation. Of these, 13 (50%) patients met
the criteria for BOS 1, 7 (27%) for BOS 2, and 6 (23%) for
BOS 3. Seventeen (40%) patients did not meet the criteria
for BOS. All patients free from BOS at the time of fundo-
plication remained so after fundoplication. Ten (77%) of the
13 patients with BOS improved their FEV1 values enough
that they no longer met the criteria for BOS after fundopli-
cation. Forty-three percent of patients with BOS 2 at the
time of fundoplication had sufficient improvement of their
FEV1 values that they no longer met the criteria for BOS
after fundoplication, whereas another 28% improved to





No. of patients 43 353
Average age (y) 43.7 15 (16-66) 47.7 14 (10-66) NS
Sex (%)
Female 18 (42) 173 (49) NS
Male 25 (58) 180 (51) NS
Underlying disease (%)
Cystic fibrosis 13 (30) 65 (18) NS
Bronchiectasis 2 (5) 5 (1) NS
OB/Rtx 3 (7) 9 (3) NS
COPD/A1Adef 15 (35) 172 (49) NS
IPF 5 (12) 46 (13) NS
PPH 1 (2) 17 (5) NS
Other 4 (9) 39 (11) NS
Type of transplant (%)
Bilateral 30 (70) 216 (61) NS
Single 13 (30) 137 (39) NS
For legend see Table 1.
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BOS 1. Only 17% of patients with BOS 3 at the time of
fundoplication had improvement in their BOS score.
Survival
Normal versus abnormal pH studies. Survival, as de-
termined by means of Kaplan-Meier analysis, in the patients
with normal pH study results was significantly improved
compared with that of patients with abnormal pH study
results (P  .047, Figure 2). Overall survival was similar at
1 year (94% in the normal pH group and 96% in the reflux
group); however, survival was substantially better at 3 and
5 years after transplantation in patients with normal pH
study results (91% and 82%, respectively) compared with in
those with reflux (77% and 48%, respectively).
Fundoplication group. Survival, as determined by
means of Kaplan-Meier analysis, in the fundoplication
group was significantly improved compared with that in the
routine transplant population (P  .013). Overall 1-year
survival in the fundoplication group was 95% versus 78% in
the overall series. Three- and 5-year survival was 86% and
71% in the fundoplication group compared with 69% and
48% in the overall series (Figure 3).
Kidney, heart, and lung allograft survival. Kaplan-
Meier actuarial survival was performed on 6-month survi-
vors of kidney, heart, and lung allografts performed after
1990 at Duke to correct for early differences in outcomes
between heart, kidney, and lung transplants as a result of
technical reasons. A significantly worse outcome for pa-
tients undergoing lung transplantation occurred (Figure 4,
A). In contradistinction, patients undergoing lung transplan-
tation documented to be without reflux or whose reflux was
treated with fundoplication have allograft survival equiva-
lent to that of patients who have undergone a kidney or heart
transplantation (Figure 4, B).
Discussion
There is a high incidence and prevalence of GERD in
patients with end-stage lung disease awaiting lung trans-
plantation. This is particularly true for those patients with
pulmonary fibrosis, in whom the incidence is greater than
50%.25,39 However, after lung transplantation, the incidence
increases to three fourths of the patients. The increase in
reflux presumably is multifactorial, including vagus nerve
injury or dysfunction, effects of immunosuppression medi-
cation on lower esophageal sphincter function, and relative
changes in intrathoracic and intra-abdominal pressures.
The consequence of GERD in patients undergoing lung
transplantation with denervated lungs, markedly impaired
cough reflex, and abnormal mucociliary function is that
Figure 1. Average FEV1 values in lung transplant recipients who also underwent fundoplication surgery for
treatment of reflux. Patients were at least 6 months from both their lung transplantations and fundoplication
procedures to allow stabilization of pulmonary function. A significant improvement in FEV1 was documented in this
group after fundoplication.
Figure 2. Effect of GERD on survival: Kaplan-Meier actuarial
survival curves for overall lung transplant recipients compared
with the group of lung transplant recipients who also underwent
fundoplication surgery after being evaluated for GERD. The fun-
doplication group had a significant survival advantage.
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prolonged contact time of aspirated gastric contents might
lead to substantially greater lung parenchymal injury. Al-
though GERD might cause repetitive direct lung injury, it is
also possible that it plays a role in augmenting the alloim-
mune response. This could occur through a number of
mechanisms. Injury to the airway epithelium causes activa-
tion and upregulation of major histocompatibility complex
class II expression. This could lead to a greater amount of
antigen presentation, either through direct or indirect anti-
gen-presentation pathways. Cell damage would increase the
amount of peptide available for presentation through indi-
rect antigen-presentation pathways. Additionally, the nor-
mal inflammatory response to aspiration injury would bring
a number of inflammatory cells, including macrophages and
monocytes, which, in addition to their ability to function as
professional antigen-presenting cells, can also provide the
appropriate costimulatory and proliferative signals to
greatly augment an alloimmune response.
The prevention of GERD by using fundoplication might
have a significant effect on both direct parenchymal injury
and on decreasing the amount of alloimmune injury. From
our data, it appears that fundoplication was particularly
successful in improving allograft function in patients who
had the earliest stages of BOS. It is likely that by eliminat-
ing airway injury caused by aspiration of gastric material
through fundoplication that allograft function is improved
both through direct airway damage and through indirect
augmented immunologic response to foreign antigen. Pa-
tients with more advanced stages of BOS did not have as
reliable an improvement in terms of function. The patho-
logic changes of peribronchial fibrosis present in advanced
stages of obliterative bronchiolitis are likely irreversible.
However, the very consistent improvement in FEV1 after
fundoplication must be compared with other treatment mo-
dalities, usually involving augmented or altered immuno-
suppression, which has had limited success.9-18 Success in
these series is defined by stabilization of the patient’s FEV1
and rarely is associated with substantial improvements in
spirometric function. Laproscopic Nissen fundoplication
was well tolerated in this patient cohort without mortality
and tolerable morbidity. From this data, we recommend in
patients with declining FEV1 values that the patient be
evaluated for the presence of GERD when consideration is
being given to fundoplication. Because many of the patients
might not have classic symptoms of GERD, a routine as-
sessment with a pH probe probably is indicated.
A significant limitation of this study and all other studies
using BOS criteria for defining chronic rejection is that
decreasing FEV1 values in the absence of other treatable
causes is a surrogate marker for obliterative bronchiolitis.
The sensitivity for obliterative bronchiolitis, the pathologic
correlative for chronic rejection, might be as low as 50% on
the basis of autopsy evaluation. Although the improvement
in spirometry in those patients with GERD after lung trans-
plantation who underwent fundoplication might not repre-
sent changes in immunologic or pathologic events, there
was a substantial survival advantage in these patients. Al-
though the cohort who underwent fundoplication was not
randomly selected, patients selected for fundoplication, par-
ticularly early in our experience, represented a group of
patients who already had demonstrated decreases in allo-
graft function. Specifically, these patients were more likely
to have BOS and had more frequent and higher grades of
acute rejection. Despite these poor prognostic factors, these
patients had improved survival and achieved survivals par-
alleling those for heart and kidney allografts.
The retrospective nature and patient selection bias are
limitations of this study. Although the lung transplant re-
cipients who had GERD and underwent fundoplication had
decreasing spirometry results and impaired lung allograft
function, they were believed to be acceptable candidates for
surgical fundoplication. With the initial results demonstrat-
ing limited morbidity and no mortality and with demonstra-
ble improvements in lung allograft function, fundoplication
has been applied earlier and to less healthy patients. Al-
though fundoplication was successful in improving lung
allograft function, medical therapy with either proton pump
inhibitors or histamine receptor antagonists did not appear
to be as efficacious. Comparisons between those patients
managed with fundoplication compared with those managed
medically are not comparable in this series because of
differences in comorbid variables. However, survival in the
fundoplication cohort was better than that for the overall
cohort, despite having more rejection episodes, more severe
rejection episodes, and a higher incidence of BOS. Patients
treated with a fundoplication, particularly early in this ex-
perience, had to survive the initial posttransplant period to
Figure 3. Effect of fundoplication on survival. Kaplan-Meier ac-
tuarial survival curves for patients evaluated for reflux by 24-hour
pH studies, comparing the group with documented reflux versus
the group with no reflux. A significant survival advantage was
seen in the patients with normal pH studies.
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be able to receive this therapy. When these 2 groups were
compared after eliminating the initial 6 months, thus remov-
ing the early mortality in the overall cohort, the difference
in survival remained significant. This has led to a number of
questions, including the following. When is the optimal
time to proceed with fundoplication in patients after lung
transplantation in documented GERD? Because of the im-
paired mucociliary function and abnormal cough reflex,
what should the amount of acid contact time be to indicate
candidacy for fundoplication?
Although this study cannot conclusively demonstrate a
linkage between obliterative bronchiolitis or BOS and
GERD, it does demonstrate that significant improvement in
lung allograft function can be achieved through the use of
fundoplication. Patients with declining FEV1 values, in ad-
dition to evaluation for acute rejection, airway complica-
tion, and infection, should also undergo evaluation for
GERD. GERD appears to represent another category of
disease processes affecting lung allografts that might be
treatable and reversible. Whether prevention of reflux dis-
ease and other nonalloimmune injury can abrogate or pre-
vent alloimmunologic injury should be a focus of future
studies.
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Discussion
Dr G. Alexander Patterson (St Louis, Mo). This was an
excellent presentation. I enjoyed it for 2 reasons. First because it
was delivered by Duane Davis, who, when he returned to Duke
after a fellowship in our program some years ago, resuscitated a
moribund transplant program. As you can see from their 400 cases
in a decade, Duke has acquired a big programmatic experience. Dr
Davis has transformed that program from virtually nothing to one
of the most active and productive lung transplant programs in the
world. He is recognized increasingly as an important contributor in
transplantation.
I also think the message is important. Bronchiolitis obliterans is
the biggest obstacle to long-term success in lung transplantation. I
also think that virtually everyone who leaves the operating room
after a bilateral lung transplantation has significant vagal dysfunc-
tion. I suspect a good number of those patients have been com-
pletely vagotomized by that operation, and I do not doubt that this
predisposes patients to increased reflux, particularly in a group of
patients who might be predisposed to reflux because of their
underlying lung disease.
A previous speaker showed us a beautiful slide of bronchiolitis
obliterans, the pathologic lesion. He also described the clinical
scoring system to describe BOS. I cannot believe that the patho-
logic lesion can be reversed with an antireflux operation or a
fundoplication. We should also remember that bronchiolitis oblit-
erans, the pathologic lesion, was described long before anybody
underwent lung transplantation. In fact, in the transplantation
context bronchiolitis obliterans was first described in patients
undergoing bone marrow transplantation.
Therefore it is not entirely clear to me what is being reversed.
I do not doubt that there are patients whose lung function is
improved, and therefore their BOS score is improved, but I do not
believe that their bronchiolitis obliterans is being corrected with
antireflux surgery.
I do have a number of questions. Duane, I am not sure what
evidence we have, apart from clinical conviction, that these pa-
tients are indeed vagotomized. Do you have any data about acid
secretion or response to sham feeding? And if these patients do
have a vagal injury, do you think it is permanent or do you think
it somehow resolves?
We have seen many transplant recipients with large distended
stomachs, air-fluid levels, retained food in the stomach, and de-
layed gastric emptying. Have any of your patients undergone a
drainage procedure in addition to their fundoplication?
I also would like your thoughts about what pathologic lesion is
being improved or reversed to demonstrate such an impressive
improvement in FEV1 values and BOS scores.
Finally, I know that you have given some thought to subjecting
this to a prospective trial. Do you really think that that this is
necessary given the compelling data that you have presented here
today?
Dr Davis. Thank you very much for your kind comments, Dr
Patterson. I am going to take the last one first.
The importance of doing a randomized trial is that I do not
think we understand the interaction between obliterative bronchi-
olitis and BOS. A nice autopsy study was presented about 3 weeks
ago demonstrating that essentially 50% of the patients who died of
obliterative bronchiolitis actually died of other causes. Therefore
the use of BOS as a surrogate marker for obliterative bronchiolitis
or the pathologic lesion is difficult at best. However, we need
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something that is sensitive enough to pick up those patients with
obliterative bronchiolitis.
We need to understand better the pathophysiologic or immu-
nologic injuries that are involved in lung allograft dysfunction. The
context of when alloimmune presentation occurs is being very
important in terms of the type of immunologic response. Why
shouldn’t the lung be more like the liver and be more—I will not
say tolerogenic—but more anergic in its response? Yet we seem to
have the clinical problem of having increased alloimmune re-
sponses. Therefore could it be that what we do with reflux injury
is that we actually present alloantigens at a time in which there is
an inflammatory response present, so that you increase the number
of peptides that can actually be presented to immune-responding
cells in the context of increased costimulatory singling et cetera?
The idea would be to put patients into a randomized trial. We have
demonstrated that we can salvage most patients who meet BOS 1
criteria and bring them back out of BOS, so that we have a safety
net. However, the idea of actually studying it in the context of
differences in the immunologic response, whether of the direct
pathway or the indirect pathway, would be very interesting and
potentially very important.
With regard to the proof of the vagal injury, we have not done
that in our transplant recipients. It is actually a very useful and
important question. Dr Steve Eubanks, one of our collaborators,
has a wonderful dog model for reflux disease, and his group is
actually studying what we are seeing clinically in that model.
Whether the various immunosuppressants also have a strong com-
ponent can be examined in our non-lung transplant population, to
just see what the effect is in the patients undergoing kidney and
heart transplantation.
In terms of drainage procedures, we have done a number of
drainage procedures, particularly with procedures early after
transplant. Those patients tended to have a longer length of stay
and a little more complicated course. What we have convinced
our laparoscopic surgeons to do now is to place a formal
gastrostomy tube and jejunostomy tube in addition to the fun-
doplication and to use the gastrostomy tube to decompress the
stomach for a short period of time. Most patients by the 3- to
6-month period actually recover a substantial amount of their
gastrointestinal function.
In terms of what the pathologic lesion is, I do not think that it
is the fibrotic lesion or the fibroproliferative lesion that was dem-
onstrated in the previous talk. That, I think, is gone, water under
the bridge. We cannot chase that. I think that is the effect that we
see when we try to do these operations for the patients with BOS
3. We are not going to reverse that process. We might be able to
stabilize it and prevent additional injury, and we certainly have
done that, staging patients who are going on to have retransplan-
tations for obliterative bronchiolitis, but if we actually are getting
to that point, we have nothing really to offer in terms of really
reversing the process.
Dr Hiran C. Fernando (Pittsburgh, Pa). Dr Davis, I enjoyed
your presentation. I have a couple of questions.
Do you have any idea how successful the laparoscopic fundo-
plication was in terms of 24-hour pH, proton pump inhibitor use,
or symptom severity scores and whether the success of the oper-
ation correlated with your outcome?
In your patient group, did you have any patients with sclero-
derma who needed antireflux surgery, and if so, what type of
operation was performed?
Dr Davis. With regard to the laparoscopic procedure, we have
not routinely studied this, but all the patients who have had a
postoperative 24-hour pH study done have had essentially no
reflux, which I think is fairly important in terms of a randomized
trial. There are 2 questions: What can you do clinically, and, from
a mechanism standpoint, what is the role of reflux? Therefore it is
going to be important to study prospectively what happens after
fundoplication. That gets into the question of what is enough reflux
to put somebody through an operation. The lungs are denervated.
The mucociliary function is very poor. Anything that gets into the
lungs is going to sit there, and it is going to cause more injury than
in anyone with a normal lung, and in the face of having alloim-
mune responses instead of syngeneic responses, you are going to
have more of an injury response.
With regard to the scleroderma, we do not categorically rule it
out, but if the esophageal function is very depressed, we do not
take those patients on primarily for this problem.
Dr Malcolm M. DeCamp (Cleveland, Ohio). Along the same
lines, in trying to bring this issue of reflux into the pretransplant
evaluation, is there a profile of a patient with reflux who you would
not transplant or who you would push toward fundoplication
before transplantation to try to avoid dealing with the problem
during the early posttransplant period? At the Brigham & Wom-
en’s Hospital, we found that we were recovering oral flora and
gastrointestinal flora 3 times more commonly in protected brush
specimens in the patients undergoing transplantation, even without
a prior history of reflux disease. Therefore I think you have helped
define an important point; we definitely disturb esophageal and
gastric function after this operation. Perhaps we ought to pay more
attention to it in our pretransplant evaluation.
Dr Davis. We prospectively study everyone at this point be-
cause of some of those data. We do not turn down patients on the
basis of just the presence of reflux if they have normal esophageal
function. What we have done more and more is subject those
patients to very early fundoplication, and in fact, if they in the
immediate posttransplant period have what appears to be an aspi-
ration episode and get reintubated, we actually put them through a
fundoplication before we get them extubated. But the presence of
it beforehand does not exclude candidacy for lung transplantation.
It just raises awareness.
Dr Ross M. Bremner (Los Angeles, Calif). Do you have any
manometric data on these patients, both preoperatively and postoper-
atively? That might help us elucidate whether this is an esophageal
body problem, a sphincter problem, or, in fact, a gastric emptying
problem. The latter might be related, in part, to possible vagal damage
at the time of transplantation, as inferred by Dr Patterson.
Second, have you had an opportunity to study any of these
patients with a dual-lumen pH probe or a probe that is placed at the
level of the laryngeal aditus to see if in fact some of this reflux is
reaching that area?
Dr Davis. With regard to manometry, the vast majority of the
patients have normal esophageal function and normal lower esoph-
ageal sphincter function. Therefore in some ways we are excluding
the patients who really have tremendous esophageal body prob-
lems, and in fact, some of the medically treated patients probably
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were turned down for fundoplication early on because of concerns
about drainage, movement, the esophageal function.
As to your second question, the fact is, what you see distally is
what you see proximally, more so than in the pretransplantation
patient. There is a bit of a degree of absolute change, so that if you
are seeing a 10% acid contact time in the distal probe, it is usually
about 7% in the proximal probe. We have never repeated the
experience where you put the tracheal pH probes in. We just have
not been able to get much buy in on that.
Dr. Walter Klepetko (Vienna, Austria). I think this is a very
important contribution.
One would assume that patients with significant reflux also
have a variety of other motility disorders, and as we all know,
those patients tend to have difficulties in achieving constant im-
munosuppressive levels. Did you have the chance to compare
those values before and after fundoplication? Although I would not
expect that the fundoplication itself has any effect on that, it would
be of interest to hear whether those patients in particular had a
highly variable level of immunosuppression.
Dr. Davis. In terms of what is happening in this patient cohort,
there has been no difference in the amount of immunosuppression.
As a matter of fact, most of those patients, particularly the ones
that hit BOS 1, BOS 2, or BOS 3 categories, have already gone
through a whole variety of changes in the immunosuppression and
augmentation of the immunosuppression. To get around the vari-
ability with absorption from the gastrointestinal system, we have
used sublingual tacrolimus, and it is absorbed wonderfully. In fact,
we stay with sublingual tacrolimus as long as there is an issue with
the gut function, and that way we are able to achieve therapeutic
levels consistently.
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